Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.27 +0.9%	$1.93	$0.40 ▼ $3.10	$181.40M	2.09	2.18 million shs	2.26 million shs
PHAR Pharming Group	$10.68 -2.9%	$10.26	$6.65 ▼ $12.61	$748.58M	0.02	6,157 shs	33,193 shs
REPL Replimune Group	$9.29 -0.4%	$9.01	$6.44 ▼ $17.00	$719.22M	0.63	857,809 shs	1.25 million shs
XERS Xeris Biopharma	$4.67 -0.6%	$4.64	$2.03 ▼ $6.07	$735.01M	0.71	2.02 million shs	3.02 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+0.89%	+5.09%	-9.92%	+291.38%	+86.07%
PHAR Pharming Group	-1.39%	+1.82%	-2.01%	+28.47%	+27.86%
REPL Replimune Group	-0.43%	+0.65%	+4.03%	+10.60%	+3.22%
XERS Xeris Biopharma	-0.64%	+0.65%	-5.27%	-8.07%	+107.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.1817 of 5 stars	3.5	1.0	4.7	2.4	1.7	1.3
PHAR Pharming Group	3.1443 of 5 stars	3.5	5.0	0.0	3.4	0.0	0.6
REPL Replimune Group	3.9765 of 5 stars	3.6	1.0	4.5	1.5	2.5	0.6
XERS Xeris Biopharma	4.1705 of 5 stars	3.4	1.0	4.2	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	134.95% Upside
PHAR Pharming Group	3.00	Buy	$30.00	181.00% Upside
REPL Replimune Group	3.13	Buy	$20.83	124.26% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	33.83% Upside

Current Analyst Ratings Breakdown

Latest CTMX, XERS, PHAR, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.33	$0.36 per share	6.22	($0.01) per share	-227.00
PHAR Pharming Group	$297.20M	2.44	$0.07 per share	148.44	$3.25 per share	3.28
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
XERS Xeris Biopharma	$222.55M	3.28	N/A	N/A	($0.20) per share	-23.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	4.73	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	355.87	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest CTMX, XERS, PHAR, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
PHAR Pharming Group	0.39	2.76	2.00
REPL Replimune Group	0.17	7.95	7.95
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
PHAR Pharming Group	0.03%
REPL Replimune Group	92.53%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
PHAR Pharming Group	2.07%
REPL Replimune Group	8.80%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
XERS Xeris Biopharma	290	156.39 million	149.25 million	Optionable

CTMX, XERS, PHAR, and REPL Headlines

Recent News About These Companies

Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $6.25

July 1 at 2:51 AM | americanbankingnews.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

June 28 at 3:27 AM | marketbeat.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

June 17, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17, 2025 | insidertrades.com

Kevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

June 16, 2025 | marketbeat.com

Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

June 9, 2025 | marketbeat.com

Leerink Partnrs Cuts Earnings Estimates for Xeris Biopharma

June 6, 2025 | marketbeat.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.comC

Mackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

June 4, 2025 | marketbeat.com

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What Happened

June 3, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

June 3, 2025 | marketbeat.com

Nuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

June 1, 2025 | marketbeat.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

CTMX, XERS, PHAR, and REPL Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.27 +0.02 (+0.89%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$2.26 -0.01 (-0.48%)

As of 09:02 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Pharming Group NASDAQ:PHAR

$10.68 -0.32 (-2.95%)

As of 06/30/2025 01:36 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Replimune Group NASDAQ:REPL

$9.29 -0.04 (-0.43%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$9.41 +0.12 (+1.29%)

As of 08:51 AM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Xeris Biopharma NASDAQ:XERS

$4.67 -0.03 (-0.64%)

As of 06/30/2025 04:00 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time